Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Montelukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 6/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | FPR1 | P21462 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | RECQL | P46063 | 1/20 | 0.87 |
| ▸ | BLM | P54132 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.87 |
| ▸ | EGFR | P00533 | 1/20 | 0.87 |
| ▸ | ESR1 | P03372 | 1/20 | 0.87 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.87 |
| ▸ | FYN | P06241 | 1/20 | 0.87 |
| ▸ | PGR | P06401 | 1/20 | 0.87 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.87 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.87 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Montelukast SCHEMBL31425566 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL9414 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL5267922 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL9415 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL29573125 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL3229836 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL29369947 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL4788140 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL8533560 | 0.99 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL6381434 | 0.99 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022368-A1 | SYSTEMS AND METHODS FOR VARIANT DETECTION IN CELLS | UNIVERSITY OF WASHINGTON (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4633613-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RUPATADINE AND MONTELUKAST | NOUCOR HEALTH S.A. (ES) | 2025-10-22 | — | — | EP | disclosed |
| CN-119241361-A | Efficient preparation method of raw material for producing montelukast sodium | 江苏阿尔法药业股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118766915-A | Application of montelukast sodium as metal beta-lactamase inhibitor | 中国人民解放军南部战区总医院 | 2024-10-15 | — | — | CN | disclosed |
| EP-4420032-A1 | METHOD AND SYSTEM EMPLOYING BOUNDARY ELEMENT METHOD WITH ADAPTIVE ORDER FOR ACOUSTIC EMISSION AND SCATTERING ANALYSIS | Siemens Industry Software NV (BE) | 2024-08-28 | — | — | EP | disclosed |
| CN-114980869-B | Large-scale production of exosome mimics and uses thereof | 儿童医学中心公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2024126772-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RUPATADINE AND MONTELUKAST | NOUCOR HEALTH, S.A. (ES) | 2024-06-20 | — | — | WO | disclosed |
| CN-117193001-B | Hyperbolic approach law sliding mode control method based on integral reinforcement learning | 南通大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117205172-A | Montelukast sodium dry suspension preparation and preparation method thereof | 迪沙药业集团有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117193001-A | Hyperbolic approach law sliding mode control method based on integral reinforcement learning | 南通大学 | 2023-12-08 | — | — | CN | disclosed |
| CN-117024340-A | Synthesis method of montelukast sodium | 迪嘉药业集团股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116940351-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116789595-A | Preparation process of special intermediate of montelukast sodium | 江苏阿尔法药业股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230248641-A1 | TOPICAL MONTELUKAST FOR TREATMENT OF ATOPIC DERMATITIS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-08-10 | — | — | US | disclosed |
| WO-2023104354-A1 | METHOD AND SYSTEM EMPLOYING BOUNDARY ELEMENT METHOD WITH ADAPTIVE ORDER FOR ACOUSTIC EMISSION AND SCATTERING ANALYSIS | SIEMENS INDUSTRY SOFTWARE NV (BE) | 2023-06-15 | — | — | WO | disclosed |
| CN-115710221-A | Synthesis method of montelukast sodium intermediate | 宿迁盛基医药科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-115583947-A | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2023-01-10 | — | — | CN | disclosed |
| WO-2022266711-A1 | SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS | Aculeus Therapeutics Pty Ltd (AU) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022200082-A1 | MULTI-DIMENSIONAL OBJECT POSE REGRESSION | SIEMENS AKTIENGESELLSCHAFT (DE) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022368-A1 | SYSTEMS AND METHODS FOR VARIANT DETECTION IN CELLS | MTREX, FANCI, DDX39B | CYSLTR1 4443/4885CYSLTR2 4568/4885CYP2C8 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.